Search results

Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

Result type

HealthTech guidance

Published

5 July 2023

Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

Result type

HealthTech guidance

Published

25 May 2005

Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

Result type

HealthTech guidance

Published

23 March 2005

Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.

Result type

HealthTech guidance

Published

23 November 2005

Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

Result type

HealthTech guidance

Published

26 April 2012

Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.

Result type

HealthTech guidance

Published

1 June 2023

This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

Result type

Clinical guideline

Last updated

3 June 2015

Topic prioritisation

Result type

Interventional procedures guidance

Status

Topic prioritisation

Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

Result type

HealthTech guidance

Published

24 May 2023

Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

Result type

HealthTech guidance

Published

27 July 2005

This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

Result type

NICE guideline

Last updated

12 January 2026

NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.

Result type

Technology appraisal guidance

Published

8 August 2024

Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

Result type

HealthTech guidance

Published

5 April 2023

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

Result type

Technology appraisal guidance

Published

28 September 2016

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.

Result type

Technology appraisal guidance

Published

22 January 2025